RxTrials Institute Drug Pipeline Alert

Swiss drugmaker Actelion and Japan’s Nippon Shinyaku have signed a license agreement for NS-304, a treatment for pulmonary arterial hypertension (PAH).
 
Under the agreement, Nippon Shinyaku will receive an upfront and additional milestone payments. The agreement also allows it  to co-develop a compound being developed by Actelion in Japan.
 
Actelion will take over a European Phase IIa study and be responsible for global development and commercialization of NS-304 outside Japan. The two companies will co-develop and co-commercialize NS-304 in Japan, Actelion said.